Roche Holding AG - Asset Resilience Ratio
Roche Holding AG (ROP) has an Asset Resilience Ratio of 9.82% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ROP FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1998–2025)
This chart shows how Roche Holding AG's Asset Resilience Ratio has changed over time. See Roche Holding AG balance sheet quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Roche Holding AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Roche Holding AG worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 0% |
| Short-term Investments | CHF9.89 Billion | 9.82% |
| Total Liquid Assets | CHF9.89 Billion | 9.82% |
Asset Resilience Insights
- Limited Liquidity: Roche Holding AG maintains only 9.82% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Roche Holding AG Industry Peers by Asset Resilience Ratio
Compare Roche Holding AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AstraZeneca PLC
MX:AZNN |
Drug Manufacturers - General | 0.03% |
|
Novartis AG
MX:NVSN |
Drug Manufacturers - General | 0.08% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 2.74% |
|
AstraZeneca PLC
F:ZEGA |
Drug Manufacturers - General | 0.03% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
Chongqing Lummy Pharmaceutical
SHE:300006 |
Drug Manufacturers - General | -0.19% |
|
Hangzhou Minsheng Healthcare Co Ltd
SHE:301507 |
Drug Manufacturers - General | 26.41% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
Annual Asset Resilience Ratio for Roche Holding AG (1998–2025)
The table below shows the annual Asset Resilience Ratio data for Roche Holding AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.82% | CHF9.89 Billion ≈ $12.51 Billion |
CHF100.70 Billion ≈ $127.32 Billion |
-0.33pp |
| 2024-12-31 | 10.16% | CHF10.34 Billion ≈ $13.08 Billion |
CHF101.80 Billion ≈ $128.70 Billion |
+4.48pp |
| 2023-12-31 | 5.67% | CHF5.13 Billion ≈ $6.49 Billion |
CHF90.47 Billion ≈ $114.38 Billion |
+0.26pp |
| 2022-12-31 | 5.42% | CHF4.78 Billion ≈ $6.04 Billion |
CHF88.15 Billion ≈ $111.45 Billion |
-1.28pp |
| 2021-12-31 | 6.70% | CHF6.18 Billion ≈ $7.81 Billion |
CHF92.32 Billion ≈ $116.71 Billion |
-0.97pp |
| 2020-12-31 | 7.67% | CHF6.61 Billion ≈ $8.35 Billion |
CHF86.14 Billion ≈ $108.90 Billion |
+0.73pp |
| 2019-12-31 | 6.94% | CHF5.77 Billion ≈ $7.29 Billion |
CHF83.09 Billion ≈ $105.05 Billion |
-1.24pp |
| 2018-12-31 | 8.19% | CHF6.43 Billion ≈ $8.13 Billion |
CHF78.52 Billion ≈ $99.27 Billion |
-1.31pp |
| 2017-12-31 | 9.49% | CHF7.28 Billion ≈ $9.20 Billion |
CHF76.68 Billion ≈ $96.94 Billion |
+3.06pp |
| 2016-12-31 | 6.44% | CHF4.94 Billion ≈ $6.25 Billion |
CHF76.82 Billion ≈ $97.12 Billion |
-0.74pp |
| 2015-12-31 | 7.18% | CHF5.44 Billion ≈ $6.88 Billion |
CHF75.76 Billion ≈ $95.78 Billion |
-3.36pp |
| 2014-12-31 | 10.54% | CHF7.96 Billion ≈ $10.06 Billion |
CHF75.54 Billion ≈ $95.50 Billion |
-2.23pp |
| 2013-12-31 | 12.76% | CHF7.93 Billion ≈ $10.03 Billion |
CHF62.17 Billion ≈ $78.60 Billion |
-1.84pp |
| 2012-12-31 | 14.60% | CHF9.46 Billion ≈ $11.96 Billion |
CHF64.81 Billion ≈ $81.93 Billion |
+2.53pp |
| 2011-12-31 | 12.07% | CHF7.43 Billion ≈ $9.40 Billion |
CHF61.58 Billion ≈ $77.85 Billion |
-2.78pp |
| 2010-12-31 | 14.85% | CHF9.06 Billion ≈ $11.45 Billion |
CHF61.02 Billion ≈ $77.15 Billion |
-6.75pp |
| 2009-12-31 | 21.60% | CHF16.11 Billion ≈ $20.36 Billion |
CHF74.56 Billion ≈ $94.27 Billion |
+0.76pp |
| 2008-12-31 | 20.84% | CHF15.86 Billion ≈ $20.05 Billion |
CHF76.09 Billion ≈ $96.20 Billion |
-5.31pp |
| 2007-12-31 | 26.15% | CHF20.45 Billion ≈ $25.85 Billion |
CHF78.18 Billion ≈ $98.84 Billion |
-2.23pp |
| 2006-12-31 | 28.38% | CHF21.12 Billion ≈ $26.70 Billion |
CHF74.41 Billion ≈ $94.08 Billion |
+4.37pp |
| 2005-12-31 | 24.01% | CHF16.66 Billion ≈ $21.06 Billion |
CHF69.36 Billion ≈ $87.70 Billion |
+6.12pp |
| 2004-12-31 | 17.90% | CHF10.39 Billion ≈ $13.14 Billion |
CHF58.08 Billion ≈ $73.42 Billion |
-0.29pp |
| 2003-12-31 | 18.19% | CHF10.82 Billion ≈ $13.68 Billion |
CHF59.49 Billion ≈ $75.21 Billion |
-1.18pp |
| 2002-12-31 | 19.37% | CHF12.39 Billion ≈ $15.67 Billion |
CHF63.99 Billion ≈ $80.91 Billion |
-9.07pp |
| 2001-12-31 | 28.44% | CHF21.41 Billion ≈ $27.07 Billion |
CHF75.29 Billion ≈ $95.18 Billion |
+2.43pp |
| 2000-12-31 | 26.01% | CHF18.09 Billion ≈ $22.87 Billion |
CHF69.53 Billion ≈ $87.91 Billion |
+2.14pp |
| 1999-12-31 | 23.87% | CHF16.81 Billion ≈ $21.26 Billion |
CHF70.43 Billion ≈ $89.04 Billion |
-1.31pp |
| 1998-12-31 | 25.19% | CHF14.07 Billion ≈ $17.79 Billion |
CHF55.88 Billion ≈ $70.65 Billion |
-- |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and tr… Read more